1. A5.10 Increases in serum cholesterol with baricitinib treatment are associated with favourable changes in apolipoprotein content and with improvement in DAS28-CRP in patients with rheumatoid arthritis. (13th February 2015) Authors: Kremer, J; Genovese, MC; Keystone, E; Taylor, P; Zuckerman, SH; Schlichting, DE; Nantz, E; Beattie, SD; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A7.17 Effects of baricitinib on multibiomarker disease activity scores and their components in a phase 2b study in moderate-to-severe rheumatoid arthritis patients. (24th February 2016) Authors: Taylor, PC; Genovese, MC; Keystone, E; Weinblatt, M; Rancourt, J; Nantz, E; Schlichting, DE; Zuckerman, SH; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0088 Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. (15th June 2017) Authors: Heijde, D van der; Durez, P; Schett, G; Naredo, E; Østergaard, M; Meszaros, G; Bello, N; Torre, I De la; Lopez-Romero, P; Schlichting, D; Nantz, E; Fleischmann, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗